Skip to content

Generalized anxiety disorder — overview

TL;DR — GAD is defined by persistent, excessive, difficult-to-control worry with associated arousal symptoms lasting ≥6 months (DeMartini 2019, PMID 30934083). DSM-5 interview estimates across 26 countries are 3.7% lifetime and 1.8% 12-month prevalence; half of lifetime cases had severe role impairment (Ruscio 2017, PMID 28297020). Antidepressants improve response versus placebo (RR 1.41, 95% CI 1.29–1.55; NNTB 7; Kopcalic 2025, PMID 39880377), CBT improves symptoms versus treatment as usual (SMD −0.74, −1.09 to −0.38; Papola 2024, PMID 37851421), and continuation escitalopram reduced relapse from 56% to 19% in responders (Allgulander 2006, PMID 16316482). The diagnosis remains contested: deleting excessiveness would raise global lifetime prevalence from 2.6% to 4.0% (Ruscio 2024, PMID 39364896), and taxometric analyses find dimensional structure (Marcus 2014, PMID 24377439). Pooled anxiety-disorder evidence is distinguished from GAD-specific evidence throughout. In a nine-disorder comparison, GAD had the second-largest pre-post placebo change (d_av 1.23, 95% CI 1.06–1.41), which contextualises—but does not explain—small drug–placebo differences (Bschor 2024, PMID 38809560). A 2026 synthesis estimated all-cause mortality RR 1.48 and natural-cause mortality RR 1.55 (Wagner 2026, PMID 42136520). Among treated respondents in World Mental Health surveys, 70% perceived treatment as helpful; modelling estimated that 29.7% would persist through up to 10 professionals, rather than that everyone must reach a tenth encounter (Stein 2021, PMID 34372811).

The condition in five sentences

Generalized anxiety disorder is defined around diffuse worry rather than a discrete phobic stimulus. It is common, female-predominant, chronic and highly comorbid: cross-national lifetime comorbidity was 81.9%, including 63.0% with mood disorders (Ruscio 2017, PMID 28297020). In primary care, clinicians recognised an emotional problem in 72.5% of pure-GAD patients but named GAD correctly in 34.4% (Wittchen 2002, PMID 12044105). Acute, continuation and collaborative-care studies use different populations, comparators and outcomes, so their effect sizes cannot rank one modality as universally “most effective.” The underlying unresolved question is whether the current threshold identifies a distinct disorder or a clinically useful point on a continuum shared with depression.

Three borders that define this condition's scope

  1. This condition owns GAD, not anxiety. Panic disorder, social anxiety disorder, specific phobias, agoraphobia and separation anxiety are not curated here; OCD is excluded and is in any case no longer classified as an anxiety disorder in DSM-5. Pooled sources appear where they must, and are labelled pooled each time. A pooled anxiety-disorder effect size is not a GAD effect size — the clearest illustration being the reference placebo-controlled CBT meta-analysis, whose overall Hedges' g=0.56 conceals large effects for GAD and small ones for PTSD, social anxiety and panic (Carpenter 2018, PMID 29451967).
  2. Comorbid depression is cross-linked, not absorbed. Genetic correlation between GAD and major depression approaches unity in women (rg=+1.00) (Kendler 2007, PMID 17121688), yet pure GAD is common in primary care (3.8% vs 1.6% comorbid) and impairs as much as pure MDD (Wittchen 2002, PMID 12044105; Hoffman 2008, PMID 17146763). Depression is curated separately.
  3. PTSD is a neighbour, not a subset. Seeded alongside this condition; each cross-links the other rather than restating it.

Map of the condition

Foundations

Page What it settles
Diagnosis and classification The DSM-5 and ICD-11 criteria, where each element came from, the instruments used to apply them, and a reliability record that has been weak since 1983
The diagnostic boundary The live dispute: excessiveness, uncontrollability, duration, symptom count; taxometrics; separability from depression; HiTOP and RDoC; the pooling hazard
Epidemiology and burden Prevalence from 0.4% to 7.4% depending on criteria, instrument and country; disability; the treatment gap

Mechanism and measurement

Page What it settles
Mechanism and models Five psychological models of worry-as-avoidance; intolerance of uncertainty and its transdiagnostic problem; neuroimaging, autonomic and genetic findings
Screening and measurement GAD-7 sensitivity 0.64 pooled versus 0.89 in development; the HAM-A as trial endpoint; USPSTF screening policy without a screening trial

Treatment

Page What it settles
Cognitive behavioural therapy Effect sizes by comparator; the applied-relaxation problem; protocol and format
Other psychological and non-drug therapies Metacognitive therapy's head-to-head win; MBSR non-inferior to escitalopram; psychodynamic therapy; exercise, acupuncture, phytoceuticals
SSRI and SNRI pharmacotherapy NNTB 7 with high certainty; the drug ranking; relapse prevention; discontinuation
Pregabalin, benzodiazepines and other agents The efficacy-versus-tolerability trade-off in its sharpest form
Digital and remote delivery Large digital effects versus a network meta-analysis finding remote CBT inferior — unresolved
Treatment-resistant GAD No agreed definition; four old augmentation trials; neurostimulation with implausible intervals

Course, populations and practice

Page What it settles
Course, relapse and long-term outcome 0.38 five-year remission in clinic cohorts versus 52% symptom-free in a community cohort; comorbidity and personality as prognostic drivers; cardiovascular outcomes
Special populations Children (CAMS), older adults (an analysis-dependent result), perinatal (4.1%/5.7% GAD-specific)
Comorbidity and primary care The 34.4% correct-diagnosis rate; collaborative care with NNT ~5
Guidelines Universal agreement on first line; disagreement on benzodiazepines, pregabalin, screening and duration; no current APA guideline for GAD
Clinical trials landscape The placebo problem; MM120 in phase 3; the live NCT pipeline
Red flags and safety concerns Suicidality including subthreshold; thyroid and other mimics; medication harms with numbers
Patient experience and advocacy A small but non-singular qualitative literature; preference strong enough to terminate a trial; the organisational landscape

The numbers worth memorising

Quantity Value Source
Lifetime prevalence, DSM-5, 26 countries 3.7% (SE 0.1); 12-month 1.8% Ruscio 2017, PMID 28297020
Lifetime prevalence without the excessiveness criterion 4.0% (vs 2.6% with it) Ruscio 2024, PMID 39364896
Severe role impairment, lifetime cases 50.6% Ruscio 2017, PMID 28297020
Lifetime comorbidity 81.9%; mood 63.0% Ruscio 2017, PMID 28297020
Antidepressant response vs placebo RR 1.41 (1.29–1.55), NNTB 7; AE-dropout NNTH 17 Kopcalic 2025, PMID 39880377
Best-ranked drug effect (HAM-A MD) Quetiapine −3.60; duloxetine −3.13; pregabalin −2.79; venlafaxine −2.69; escitalopram −2.45 Slee 2019, PMID 30712879
CBT vs treatment as usual SMD −0.74 (−1.09 to −0.38); third-wave −0.76; relaxation −0.59 Papola 2024, PMID 37851421
CBT at ≥12 months in GAD Hedges' g=0.22 (k=10) — smallest among anxiety disorders van Dis 2020, PMID 31758858
Relapse off vs on escitalopram 56% vs 19% over 24–76 weeks Allgulander 2006, PMID 16316482
Five-year remission probability (clinic cohort) 0.38 Yonkers 2000, PMID 10974960
Placebo pre-post effect in GAD trials d_av 1.23 (1.06–1.41) — second-highest of nine disorders Bschor 2024, PMID 38809560
GAD-7 at ≥10, pooled Sensitivity 0.64 (0.56–0.72), specificity 0.91 (0.87–0.93) Aktürk 2025, PMID 40130828
Collaborative care in primary care NNT 5.27 response, 5.50 remission at 12 months Roy-Byrne 2010, PMID 20483968
Treatment gap 75.7% (India); 96.1% not seeking help (Bangladesh); ~50% untreated (WMH) Jayasankar 2023, PMID 38298878; Sarkar 2025, PMID 41061374; Ruscio 2017, PMID 28297020
All-cause mortality RR 1.48 (1.23–1.78); suicide mortality RR 1.93 (1.17–3.17); natural-cause RR 1.55 (1.19–2.02) Wagner 2026, PMID 42136520 (165 studies, 7.4M people with anxiety/stress-related disorders)
Treatment perceived helpful, of those treated 70%; but only 34.6% ever obtain treatment and just 29.7% would persist through enough professionals to reach the modelled ceiling Stein 2021, PMID 34372811
Placebo pre-post effect d_av 1.23 (1.06–1.41), second of nine psychiatric disorders Bschor 2024, PMID 38809560

Where this condition is genuinely unresolved

  1. Should excessive worry remain a required criterion? Published, from the group that produced the cross-national epidemiology, and unanswered (Ruscio 2024, PMID 39364896).
  2. What works for GAD without comorbid depression? The trials either exclude comorbidity or allow all of it (Kopcalic 2025, PMID 39880377; Chen 2019, PMID 31494377).
  3. Does screening change outcomes, or only detection? A B recommendation issued with no positive screening trial (USPSTF 2023, PMID 37338866; O'Connor 2023, PMID 37338868).
  4. What maintains remission over years rather than weeks? Longest acute-phase trial: 28 weeks; disorder measured in decades.
  5. Is guided digital CBT equivalent to face-to-face CBT in GAD? Two evidence bases, opposite answers (Pauley 2023, PMID 34047264; Liu 2025, PMID 40506439).

Full tiered set with a "dots not yet connected" table: OPEN-QUESTIONS.md.

Reading paths

Every page in this condition is listed in the map above. Neighbouring conditions: PTSD and depression.

References

  1. DeMartini J, et al. Generalized Anxiety Disorder. Ann Intern Med. 2019;170:ITC49-ITC64. PMID 30934083
  2. Ruscio AM, et al. Cross-sectional Comparison of the Epidemiology of DSM-5 Generalized Anxiety Disorder Across the Globe. JAMA Psychiatry. 2017;74:465-475. PMID 28297020
  3. Ruscio AM, et al. The case for eliminating excessive worry as a requirement for generalized anxiety disorder. Psychol Med. 2024;54:3447-3458. PMID 39364896
  4. Marcus DK, et al. The latent structure of generalized anxiety disorder in midlife adults. Psychiatry Res. 2014;215:366-71. PMID 24377439
  5. Kopcalic K, et al. Antidepressants versus placebo for generalised anxiety disorder (GAD). Cochrane Database Syst Rev. 2025;1:CD012942. PMID 39880377
  6. Papola D, et al. Psychotherapies for Generalized Anxiety Disorder in Adults. JAMA Psychiatry. 2024;81:250-259. PMID 37851421
  7. Allgulander C, et al. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol. 2006;9:495-505. PMID 16316482
  8. Bschor T, et al. Differential Outcomes of Placebo Treatment Across 9 Psychiatric Disorders. JAMA Psychiatry. 2024;81:757-768. PMID 38809560
  9. Lijster JM, et al. The Age of Onset of Anxiety Disorders. Can J Psychiatry. 2017;62:237-246. PMID 27310233
  10. Wittchen HU, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry. 2002;63 Suppl 8:24-34. PMID 12044105
  11. Roy-Byrne P, et al. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA. 2010;303:1921-8. PMID 20483968
  12. Carpenter JK, et al. Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials. Depress Anxiety. 2018;35:502-514. PMID 29451967
  13. Kendler KS, et al. The sources of co-morbidity between major depression and generalized anxiety disorder in a Swedish national twin sample. Psychol Med. 2007;37:453-62. PMID 17121688
  14. Hoffman DL, et al. Human and economic burden of generalized anxiety disorder. Depress Anxiety. 2008;25:72-90. PMID 17146763
  15. Slee A, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019;393:768-777. PMID 30712879
  16. van Dis EAM, et al. Long-term Outcomes of Cognitive Behavioral Therapy for Anxiety-Related Disorders. JAMA Psychiatry. 2020;77:265-273. PMID 31758858
  17. Yonkers KA, et al. Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry. 2000;176:544-9. PMID 10974960
  18. Aktürk Z, et al. Generalized Anxiety Disorder 7-item (GAD-7) and 2-item (GAD-2) scales for detecting anxiety disorders in adults. Cochrane Database Syst Rev. 2025;3:CD015455. PMID 40130828
  19. Jayasankar P, et al. Current prevalence and determinants of generalized anxiety disorder from a nationally representative, population-based survey of India. Indian J Psychiatry. 2023;65:1244-1248. PMID 38298878
  20. Sarkar AA, et al. Prevalence, correlates, and treatment gap of generalized anxiety disorder among adults in Bangladesh. J Anxiety Disord. 2025;116:103077. PMID 41061374
  21. Chen TR, et al. Pharmacological and psychological interventions for generalized anxiety disorder in adults: A network meta-analysis. J Psychiatr Res. 2019;118:73-83. PMID 31494377
  22. US Preventive Services Task Force. Screening for Anxiety Disorders in Adults. JAMA. 2023;329:2163-2170. PMID 37338866
  23. O'Connor EA, et al. Anxiety Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2023;329:2171-2184. PMID 37338868
  24. Pauley D, et al. Two decades of digital interventions for anxiety disorders. Psychol Med. 2023;53:567-579. PMID 34047264
  25. Liu S, et al. CBT treatment delivery formats for generalized anxiety disorder. Transl Psychiatry. 2025;15:197. PMID 40506439
  26. Wagner E, et al. Risk of all-cause and cause-specific mortality, and suicide attempt in people with anxiety and stress-related disorders: a systematic review, meta-analysis and meta-regression analysis of 165 studies. World Psychiatry. 2026;25:307-320. PMID 42136520
  27. Stein DJ, et al. Perceived helpfulness of treatment for generalized anxiety disorder: a World Mental Health Surveys report. BMC Psychiatry. 2021;21:392. PMID 34372811